Cohen, Yael C.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine

Multiple Myeloma Research and TreatmentsSingle-cell and spatial transcriptomics

Cited by 263

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Cohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 235

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 121

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., et al. (2021) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 25

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.

van de Donk, N. W. C. J., Agha, M. E., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W., Schecter, J. M., De Braganca, K. C., Varsos, H., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 20

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 7